A systematic review and meta-analysis of erythropoietin in experimental stroke
Mikael Jerndal, Kalle Forsberg, Emily S Sena, Malcolm R Macleod, Victoria E O'Collins, Thomas Linden, Michael Nilsson, David W Howells
Journal of Cerebral Blood Flow and Metabolism | NATURE PUBLISHING GROUP | Published : 2010
Erythropoietin (EPO) has shown promise as a neuroprotectant in animal models of ischemic stroke. EPO is thought not only to protect neurons from cell death, but also to promote regeneration after stroke. Here, we report a systematic review and meta-analysis of the efficacy of EPO in animal models of focal cerebral ischemia. Primary outcomes were infarct size and neurobehavioral outcome. Nineteen studies involving 346 animals for infarct size and 425 animals for neurobehavioral outcome met our inclusion criteria. Erythropoietin improved infarct size by 30.0% (95% CI: 21.3 to 38.8) and neurobehavioral outcome by 39.8% (33.7 to 45.9). Studies that randomized to treatment group or that blinded a..View full abstract
We express our gratitude to Professor Geoff Donnan for constructive discussions regarding this paper. This study was supported by The Australian NHMRC, The Swedish Research Council, the region of West Sweden, the ALF Funding Sources Goteborg, the Edit Jakobsson Foundation, the Elsa and Gustav Lindh Foundation, and the Sten A Olsson foundation for Research and Culture.